Skip to main content
NCBI home page
Gut logoLink to Gut
. 2002 May;50(Suppl 4):iv36–iv41. doi: 10.1136/gut.50.suppl_4.iv36

The potential role of acid suppression in functional dyspepsia: the BOND, OPERA, PILOT, and ENCORE studies

N Talley, K Lauritsen
PMCID: PMC1867693  PMID: 11953346

Full Text

The Full Text of this article is available as a PDF (197.7 KB).

Figure 1 .

Figure 1

Open in a new tab

Percentage of patients with (A) complete relief of symptoms and (B) sufficient control of symptoms after four weeks of treatment with omeprazole 20 mg or 10 mg once daily, or placebo (BOND and OPERA).

Figure 2 .

Figure 2

Open in a new tab

Percentage of patients in the individual subgroups of ulcer-like, reflux-like, and dysmotility-like functional dyspepsia who had complete relief of symptoms after four weeks of treatment with omeprazole 20 mg or 10 mg once daily, or placebo. NS, not significant (BOND and OPERA).

Figure 3 .

Figure 3

Open in a new tab

Percentage of patients with complete relief of symptoms after four weeks of treatment with omeprazole 20 mg or 10 mg once daily, or placebo, according to Helicobacter pylori (Hp) status (BOND and OPERA). Hp-, H pylori negative; Hp+, H pylori positive.

Figure 4 .

Figure 4

Open in a new tab

(A) Mean number of days on medication, (B) mean number of clinic visits, and (C) patient quality of life measured by the psychological general well being index, during a three month follow up period in patients with either complete relief of symptoms or persistent symptoms after a four week course of therapy (BOND and OPERA); 95% confidence intervals are also shown.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bates S., Sjödén P. O., Fellenius J., Nyrén O. Blocked and nonblocked acid secretion and reported pain in ulcer, nonulcer dyspepsia, and normal subjects. Gastroenterology. 1989 Aug;97(2):376–383. doi: 10.1016/0016-5085(89)90073-5. [DOI] [PubMed] [Google Scholar]
  2. Blum A. L., Arnold R., Stolte M., Fischer M., Koelz H. R. Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status. The Frosch Study Group. Gut. 2000 Oct;47(4):473–480. doi: 10.1136/gut.47.4.473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Collen M. J., Loebenberg M. J. Basal gastric acid secretion in nonulcer dyspepsia with or without duodenitis. Dig Dis Sci. 1989 Feb;34(2):246–250. doi: 10.1007/BF01536059. [DOI] [PubMed] [Google Scholar]
  4. George A. A., Tsuchiyose M., Dooley C. P. Sensitivity of the gastric mucosa to acid and duodenal contents in patients with nonulcer dyspepsia. Gastroenterology. 1991 Jul;101(1):3–6. doi: 10.1016/0016-5085(91)90453-r. [DOI] [PubMed] [Google Scholar]
  5. Goves J., Oldring J. K., Kerr D., Dallara R. G., Roffe E. J., Powell J. A., Taylor M. D. First line treatment with omeprazole provides an effective and superior alternative strategy in the management of dyspepsia compared to antacid/alginate liquid: a multicentre study in general practice. Aliment Pharmacol Ther. 1998 Feb;12(2):147–157. doi: 10.1046/j.1365-2036.1998.0284f.x. [DOI] [PubMed] [Google Scholar]
  6. Jones R. H., Baxter G. Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice. Aliment Pharmacol Ther. 1997 Jun;11(3):541–546. doi: 10.1046/j.1365-2036.1997.00179.x. [DOI] [PubMed] [Google Scholar]
  7. Kagevi I., Löfstedt S., Persson L. G. Endoscopic findings and diagnoses in unselected dyspeptic patients at a primary health care center. Scand J Gastroenterol. 1989 Mar;24(2):145–150. doi: 10.3109/00365528909093029. [DOI] [PubMed] [Google Scholar]
  8. Mason I., Millar L. J., Sheikh R. R., Evans W. M., Todd P. L., Turbitt M. L., Taylor M. D. The management of acid-related dyspepsia in general practice: a comparison of an omeprazole versus an antacid-alginate/ranitidine management strategy. Compete Research Group [corrected]. Aliment Pharmacol Ther. 1998 Mar;12(3):263–271. doi: 10.1046/j.1365-2036.1998.00282.x. [DOI] [PubMed] [Google Scholar]
  9. Meineche-Schmidt V., Talley N. J., Pap A., Kordecki H., Schmid V., Ohlsson L., Wahlqvist P., Wiklund I., Bolling-Sternevald E. Impact of functional dyspepsia on quality of life and health care consumption after cessation of antisecretory treatment. A multicentre 3-month follow-up study. Scand J Gastroenterol. 1999 Jun;34(6):566–574. doi: 10.1080/003655299750026010. [DOI] [PubMed] [Google Scholar]
  10. Nyrén O., Adami H. O., Gustavsson S., Lindgren P. G., Löf L., Nyberg A. The "epigastric distress syndrome". A possible disease entity identified by history and endoscopy in patients with nonulcer dyspepsia. J Clin Gastroenterol. 1987 Jun;9(3):303–309. [PubMed] [Google Scholar]
  11. Nyrén O., Adami H. O., Gustavsson S., Löf L., Nyberg A. Social and economic effects of non-ulcer dyspepsia. Scand J Gastroenterol Suppl. 1985;109:41–47. doi: 10.3109/00365528509103934. [DOI] [PubMed] [Google Scholar]
  12. Samsom M., Verhagen M. A., vanBerge Henegouwen G. P., Smout A. J. Abnormal clearance of exogenous acid and increased acid sensitivity of the proximal duodenum in dyspeptic patients. Gastroenterology. 1999 Mar;116(3):515–520. doi: 10.1016/s0016-5085(99)70171-x. [DOI] [PubMed] [Google Scholar]
  13. Stanghellini V., Tosetti C., De Giorgio R., Barbara G., Salvioli B., Corinaldesi R. How should Helicobacter pylori negative patients be managed? Gut. 1999 Jul;45 (Suppl 1):I32–I35. doi: 10.1136/gut.45.2008.i32. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Talley N. J. Drug treatment of functional dyspepsia. Scand J Gastroenterol Suppl. 1991;182:47–60. [PubMed] [Google Scholar]
  15. Talley N. J., Meineche-Schmidt V., Paré P., Duckworth M., Räisänen P., Pap A., Kordecki H., Schmid V. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther. 1998 Nov;12(11):1055–1065. doi: 10.1046/j.1365-2036.1998.00410.x. [DOI] [PubMed] [Google Scholar]
  16. Talley N. J., Phillips S. F. Non-ulcer dyspepsia: potential causes and pathophysiology. Ann Intern Med. 1988 Jun;108(6):865–879. doi: 10.7326/0003-4819-108-6-865. [DOI] [PubMed] [Google Scholar]
  17. Talley N. J. Review article: functional dyspepsia--should treatment be targeted on disturbed physiology? Aliment Pharmacol Ther. 1995 Apr;9(2):107–115. doi: 10.1111/j.1365-2036.1995.tb00359.x. [DOI] [PubMed] [Google Scholar]
  18. Talley N. J., Zinsmeister A. R., Schleck C. D., Melton L. J., 3rd Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology. 1992 Apr;102(4 Pt 1):1259–1268. [PubMed] [Google Scholar]
  19. Veldhuyzen van Zanten S. J., Cleary C., Talley N. J., Peterson T. C., Nyrén O., Bradley L. A., Verlinden M., Tytgat G. N. Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials. Am J Gastroenterol. 1996 Apr;91(4):660–673. [PubMed] [Google Scholar]
  20. el-Omar E., Penman I., Ardill J. E., McColl K. E. A substantial proportion of non-ulcer dyspepsia patients have the same abnormality of acid secretion as duodenal ulcer patients. Gut. 1995 Apr;36(4):534–538. doi: 10.1136/gut.36.4.534. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES